Skip to main content
News & Announcements

Quotient Sciences Expands UK Formulation and Analytical Capabilities

Drug Development & Manufacturing Partners - Quotient Sciences
NOTTINGHAM, UK; August 24,2022 – Quotient Sciences, a drug development and manufacturing accelerator, has completed a £1.5 million expansion of its early development and manufacturing facility in Reading, UK.

The investment has doubled formulation development and analytical capabilities at the site, increased office space, and created 40 new technical and scientific jobs including formulators and analytical chemists.

“Our investment in Reading is in response to strong market demand, direct feedback from our customer base, and to maximize utilization of our UK-based operational footprint,,” said Mark Egerton, CEO of Quotient Sciences.

“As well as increased formulation development and analytical capabilities, the expansion increases our capacity to support  programs as they progress through development phases, providing our customers with further improved services.”

Quotient Sciences employs more than 1,300 talented individuals across six operating sites in the UK and US. The 48,000 sq ft Reading facility currently employs 75 people across a range of scientific disciplines.

Egerton added: “We are committed to a growth strategy that supports our customers on both sides of the Atlantic, with stand-alone development and manufacturing services, or fully integrated Translational Pharmaceutics® programs that deliver substantial time and cost benefits.

“We will continue to liaise with existing and potential customers to ensure we are meeting their current and future needs and expect to announce further expansions of both UK and US operations in the near future.”

Acquired in 2017, Quotient Sciences tripled the manufacturing footprint of the Reading facility in 2018, increasing the total number of manufacturing suites to 13. The site focuses on small-molecule drug products from the pre-clinical stage through to Phase I-III clinical trials, with significant expertise in poorly soluble compounds and a broad range of technologies including spray drying, hot-melt extrusion, lipidic systems, and particle size reduction methodologies.

View the press release here

Latest news

News & Announcements, Dr. Vanessa Zann, artificial intelligence Outsourcing Pharma interview with Dr. Vanessa Zann By: Dr. Vanessa Zann
Learn more
News & Announcements, Interviews, Thierry Van Nieuwenhove, artificial intelligence Executive interview at DCAT with Life Sciences Knowledge Hub featuring Thierry Van Nieuwenhove
Learn more